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Background: Inflammation in adipose tissue (AT) during obesity causes impaired AT function. Although multiple
extracellular matrix (ECM) proteins are expressed in AT their potential role in adipose tissue inflammation is unclear.
Biglycan, a pro-inflammatory ECM gene, is highly enriched in adipose tissue. However, whether it is correlated with
adipose tissue inflammation is unknown. We provide evidence in support of a strong association between biglycan
expression and inflammatory status of adipose tissue.
Methods: C57BL6 mice were fed either a control (10% fat calories) or a high fat diet (HFD) (60% fat calories) for
8 weeks. Adipose tissue was analyzed for the expression of biglycan, IL-6 and TNFα. Biglycan knockout or wild type
were also fed a high fat diet for 8 weeks and the expression of inflammatory genes in the mesenteric adipose tissue
was examined. To test anti-inflammatory treatment on biglycan expression, a group of mice were fed either the low
fat or high fat diet for eight weeks supplemented with either saline or sodium salicylate @ 25mg/100ml in their
drinking water.
Results: Mice on HFD had an increase in ECM genes (BGN and COL1A1), inflammatory genes (IL-6 and TNFα) in
both the subcutaneous and epididymal depots. However, correlation analysis only shows a positive correlation
between biglycan, IL-6 and TNFα expression. In addition, lower expression of IL-6 and CD68 was found in the
mesenteric adipose tissue of biglycan knockout mice compared to the wild type. Sodium salicylate treatment
reduced subcutaneous adipose tissue expression of BGN, COL1A1, and COL6A1 and a concurrent downregulation of
TNFα and IL-6 and TLR4 expression. Salicylate also lowered the serum TGFβ1 levels.
Conclusion: Biglycan expression correlates with adipose tissue inflammation, especially in the subcutaneous depot
compared to the epididymal depot. This is supported by the greater effect of sodium salicylate in attenuating both
inflammatory and ECM gene expression the subcutaneous adipose depot compared to the epididymal depot. These
results show that inflammatory state may explain the induction of biglycan, and perhaps, other ECM genes in
adipose tissue.Background
Obesity is associated with chronic low-grade inflamma-
tion in adipose tissue which predisposes to metabolic
disorders like insulin resistance and type II diabetes and
cardiovascular complications [1-3]. Although multiple
ECM proteins are present in adipose tissue, it is cur-
rently unknown if there is a link between these proteins
and adipose tissue inflammation. Extracellular matrix* Correspondence: kajuwon@purdue.edu
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reproduction in any medium, provided the orproteins, apart from providing mechanical support to
adipocytes and other cells, also participate in a variety of
signaling events including activation of inflammatory sig-
nals [4,5]. This evidence is supported in mouse models
of obesity such as the ob/ob and the db/db mice which
have elevated expression of inflammatory markers and
ECM genes [6]. Furthermore, phenotypic changes
induced by the action of proinflammatory mediators on
preadipocytes lead to increased synthesis of ECM com-
ponents in the subcutaneous adipose tissue of obese
human subjects [7]. Information is currently lacking on
the role of specific ECM proteins in the regulation of ATl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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flammatory effect [8]. Biglycan activates inflammatory
pathways by signaling through toll-like receptor (TLR) 2
and 4 in macrophages leading to secretion of TNFα and
mature IL-1β [8]. A more recent discovery indicates that
biglycan activates the inflammasome pathway by indu-
cing an interaction between the TLR2/4 and the puriner-
gic P2X(4)/P2X(7) receptors, which are part of the
nucleotide-binding oligomerization domain-like recep-
tors (NLRP3/ASC) [5]. This interaction is considered ne-
cessary for biglycan induction of IL-1β in macrophages.
As shown with receptor knockout mice, biglycan is able
to activate these inflammatory pathways through direct
binding to these receptors, thus triggering downstream
signaling pathways [5,8]
We have recently shown that biglycan is highly expressed
in subcutaneous adipose tissue of obese human subjects
that also display elevated expression of inflammatory cyto-
kine TNFα and absence of biglycan is associated with
reduced expression of TNFα in mice [9]. Although the
exact stimulus for the induction of biglycan expression in
obesity is unknown, because biglycan expression can be
induced by inflammatory cytokines [8], saturated fatty
acids, which are also proinflammatory, or inflammatory
cytokines may mediate the increased expression of bigly-
can in AT in obesity. In this report, we have employed an
anti-inflammatory treatment with sodium salicylate to de-
termine if therapeutic reduction of AT inflammation is ac-
companied by decreased ECM expression.
The therapeutic effects of sodium salicylate are well
known from the late 19th century. However, limited stud-
ies have investigated the detailed molecular targets of sa-
licylate, especially in AT. The anti-inflammatory effect of
salicylate compounds is partly through the inhibition of
cyclooxygenase (COX) enzymes involved in prostaglan-
din synthesis [10]. Later studies also showed that this
anti-inflammatory action included activation of p38
MAPK [11] and inhibition of nuclear transcription factor
kappa B (NF-kB) and its upstream activators [12,13].
High doses of salicylate compounds inhibit the transloca-
tion of transcription factor NF-kB into the nucleus by
preventing the degradation of IkBα [12] through the spe-
cific inhibition of IKKβ kinase activity [14]. Salicylates in
high doses can also exert metabolic benefits such as im-
provement in fasting glucose and insulin levels in both
obese and diabetic subjects [15-17] and lowering of
blood triglyceride and free fatty acid concentrations
[15,18] and increase in insulin sensitivity [10]. We show
herein that reduction in AT inflammation corresponds
to reduced biglycan expression. Thus, inflammatory state
is a key factor responsible for AT ECM expression.
Understanding the connection between biglycan and adi-
pose tissue inflammation will expand our understanding
of the role of ECM components in inflammation.Methods
Animals and experimental design
All mice used for the experiment were housed in the
pathogen free facility at the Purdue Small Animal Housing
facility. In the first experiment conducted to determine the
effect of high fat diet on biglycan and inflammatory gene
expression, male C57BL/6J mice (Jackson Laboratories,
Bar Harbor, Maine) at 8 weeks of age were divided equally
(8 mice per group) between a control diet with 10 kcal %
fat (D12450Bi) and a high fat diet with 60 kcal % fat
(D12492i) (Research Diets, New Brunswick, NJ) and fed
for 8 weeks. Thereafter, epididymal AT was analyzed for
biglycan and inflammatory gene expression. The second
experiment was carried out to test the anti-inflammatory
effect of salicylate. Thirty-two male C57BL/6J mice at
8 weeks old were assigned to either a control diet (n= 16)
or a high fat diet (n= 16) as described above. Each diet
group was split into two groups (8 mice per group) and
given either plain water or water with sodium salicylate at
a dose of 25mg/100 ml. After 8 weeks on treatments, mice
were killed with CO2 asphyxiation and adipose tissues
were snap-frozen in liquid nitrogen and stored at -80°C for
gene expression and immunoblotting assays. Additional
analysis of effect of biglycan absence on inflammatory gene
expression was conducted in AT from biglycan knockout
and wild type mice as described previously [9]. All animal
protocols were approved by the Purdue Animal Care and
Use Committee.
Glucose tolerance test (GTT)
Animals were fasted 12 hours prior to GTT. Mice were
administered a 50% dextrose solution via intraperitoneal
(IP) injection at 2.0 g/kg body weight. Tail blood was col-
lected at 0 (basal), 15, 30, 45, 60, and 120 minutes re-
spectively after the glucose injection for the
determination of blood glucose concentration with an
automatic glucometer (Freestyle, Alameda, CA).
RNA extraction and quantitative RT-PCR
Total RNA from epididymal and subcutaneous AT and
gastrocnemius muscle was extracted using TRIzolW
(Invitrogen, Carlsbad, CA) and reverse transcribed with
the MMLV reverse transcriptase (Promega, Madison,
WI). Real-time PCR was performed using the MyiQ real-
time PCR detection system (Bio-Rad, Hercules, CA) with
the Faststart SYBR mix (Roche, Indianapolis, IN). Pri-
mers were designed from gene sequences in the NCBI
database with the Invitrogen primer design software.
Gene specific mRNA abundance was determined from
the threshold cycle (Ct) for respective genes and normal-
ized against the Ct for 18S using the ΔΔCt method. Data
are expressed as fold changes relative to a control sample
which was also used for correcting run-to-run variations.
List of primers is as described previously [9].
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Serum was separated from whole blood by centrifugation
at 5,000g for 5 minutes. TGFβ1 protein level was mea-
sured in the serum samples using Human/Mouse TGFβ1
ELISA kit (eBioscience, San Diego, CA) according to the
manufacturer’s instructions.
Statistical analysis
Data were examined for normality and analyzed using
the GLM procedures (SAS Inst. Inc., Cary, NC). Turkey
analysis was conducted for mean separation. Differences
were considered significant at P< 0.05. P values between
0.05 and 0.1 were considered showing a strong tendency
for significance. Values in the text are means ± SEM.
Results
High fat diet induces biglycan and inflammatory gene
expression
First, we determined the expression of biglycan and in-
flammatory genes IL-6 and TNFα in epididymal tissue
after a high fat diet. As shown in Figure 1, increased
expression of biglycan resulted from high fat diet feed-
ing. High fat diet also significantly induced the expres-
sion of IL-6 and TNFα. There was also an increase in
the expression of other ECM genes such as COL1A1
and COL6A1 (data not shown). To determine if there
was any correlation between the expression of biglycan
and inflammatory genes, correlation analysis was run
between the ECM genes (biglycan, COL1A1 and
COL6A1) and the inflammatory genes. Significant cor-
relation was found only between biglycan, IL-6 and
TNFα (Table 1). Therefore, we focused on biglycan for
the rest of the study.Figure 1 Effect of diet on the expression of biglycan and
inflammatory genes. Male C57BL/6J mice fed either a low fat diet
(10% fat calories) or a high fat diet (HFD) (60% fat calories) for
8 weeks. Epididymal fat RNA was obtained and subjected to RT-PCR
analysis. Bars represent means and SE of treatments (n = 8). Bars with
different superscripts are different (P< 0.05).Reduced inflammation in biglycan knockout mice
We had earlier reported a decreased expression of TNFα
in the adipose tissue of biglycan knockout mice [9].
Therefore we analyzed other inflammatory marker genes,
IL-6 and CD68. Similar to TNFα, decreased expression
of IL-6 and CD68 was found in biglycan knockout mice
compared to the wild type (Figure 2). In addition, glu-
cose tolerance test conducted on the WT and biglycan
knockout mice (Figure 2b) revealed better clearance of
injected glucose by the knockout mice, an indication of
improved metabolic profile in the knockout animals rela-
tive to WT. Thus, the absence of biglycan lowers expres-
sion of inflammatory makers and leads to improved
metabolic profile. This suggests that biglycan could be
involved in the development of AT inflammation and
metabolic dysregulation in obesity.Diet and salicylate effect on growth and body
composition
The association between biglycan and inflammatory gene
expression suggests that biglycan may be involved in the
induction of inflammatory gene expression or vice versa.
Indeed, the lower expression of inflammatory genes in
the biglycan knockout mice strongly supports a major
role for biglycan or biglycan-associated processes in the
regulation of inflammatory gene expression. However, to
determine whether inflammation is involved in the regu-
lation of biglycan expression, we tested the effect of sali-
cylate, an anti-inflammatory pharmacological compound
in mice fed either a control or a high fat diet. As
expected, mice on the high fat diet had a higher body
weight than those on the control diet (P< 0.0001)
(Table 2). However, sodium salicylate had no effect on
the body weight of the mice. As predicted, subcutane-
ous and visceral AT mass of the mice on the HFD was
greater than in mice on control diet (P< 0.0001). Al-
though there was no salicylate effect on the overall
body weight, mice on the HFD receiving sodium sali-
cylate had a lower subcutaneous AT weight (P< 0.07).
This may suggest that sodium salicylate prevents fat
deposition in this depot.Table 1 Correlation analysis between biglycan expression




BGN 0.38* (0.002) 0.55* (0.0001)
IL-6 0.38*(0.002) 0.66*(0.0001)
TNFα 0.55*(0.0001) 0.66*(0.0001)
*Significant positive correlation between BGN and IL6 (P< 0.002) and TNFα
(P< 0.0001).
Figure 2 a. Expression of inflammatory genes in wild type or
biglycan knockout mice. Mice were given a high fat diet for 9 weeks.
Expression of inflammatory genes was determined by RT-PCR. Bars
represent means (n= 4) and SE of treatments. Bars with different
superscripts are different (P< 0.05). b. Glucose Tolerance Test (GTT) in
wild type (WT) and biglycan null (KO) mice. Mice received
intraperitoneal injection of 50% dextrose solution at 2g/kg BW. Blood
glucose concentration was measured at 0, 15, 30, 45, 60 and
120 minutes. KO mice are more sensitive than WT mice.*; P< 0.05.
Table 2 Body composition in mice on control or high fat diet
Parameters Diet
Control
Water(n = 8) Sal.C10(n = 8) Water(n =
Body Weight 33.45 ± 1.18b 31.03 ± 1.26b 39.33 ± 1.2
Depots
SubCut1(%) 1.60 ± 0.19c 1.84 ± 0.20c 4.30 ± 0.20
EPI2(%) 2.40 ± 0.25b 2.94 ± 0.27b 5.02 ± 0.27
Retro3(%) 0.78 ± 0.10b 0.83 ± 0.10b 1.75 ± 0.10
Liver(%) 4.09 ± 0.22a 4.04 ± 0.23ab 3.39 ± 0.23
Muscle4(%) 1.31 ± 0.12a 1.02 ± 0.12ab 1.13 ± 0.12
a,b,c; superscripts represent significant differences in mean values; P< 0.05.
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cytokine genes
In the subcutaneous AT (Figure 3), HFD upregulated the
expression of key ECM genes (BGN, COL1A1 and
COL6A1 (P< 0.0001). High fat diet also induced the ex-
pression of TGFβ1 (P< 0.002), IL-10 (P< 0.05) and
TLR4 (P< 0.0005). However, sodium salicylate counter-
acted the effect of HFD and led to a significantly lower
expression of BGN (P< 0.04) and COL6A1 (P< 0.01).
Additionally, salicylate treatment downregulated the ex-
pression of TNFα (P< 0.0006) and TLR4 (P< 0.07).
Therefore, although HFD induced the expression of
these genes, salicylate treatment effectively minimized
HFD-induced subcutaneous AT expansion with an at-
tendant downregulation of inflammatory and ECM gene
expression.
In the epididymal AT (Figure 4), HFD induced the ex-
pression of BGN, COL1A1, COL6A1, TGFβ1, TNFα,
IL-10, TLR4 (P< 0.0001) and IL-6 (P< 0.03). However,
there was a reduced overall effect of sodium salicylate
in the epididymal adipose depot compared to the sub-
cutaneous depot. Nevertheless, salicylate reduced the
circulating concentration of TGFβ1, a profibrotic pro-
tein involved in the induction of many ECM genes in-
cluding biglycan, indicating that it could have an overall
anti-fibrotic effect (Figure 5).
Discussion
Our study has shown that the increased inflammation in
obesity also involves elevated expression of ECM genes
in AT. The strong association between biglycan expres-
sion and that of inflammatory genes supports a major
role for this protein in AT inflammation. Indeed, as we
have shown previously [9], reduced expression of TNFα
was found in the mesenteric AT of biglycan knockout
mice. We have extended this finding to include other(HFD)
P-Value
High Fat
8) Sal.C5(n = 8) Diet Sal.C Diet*Sal.C
6a 40.20 ± 1.26a 0.0001 0.51 0.20
a 3.27 ± 0.20b 0.0001 0.07 0.004
a 4.88 ± 0.27a 0.0001 0.43 0.20
a 1.74 ± 0.10a 0.0001 0.87 0.79
b 3.66 ± 0.23ab 0.03 0.65 0.50
ab 0.87 ± 0.15b 0.20 0.04 0.91
Figure 3 Effect of sodium salicylate (Sal.C) treatment on
expression of genes in mice on low fat or high fat diet in the
subcutaneous adipose tissue. Subcutaneous RNA was analyzed for
the expression of ECM genes (a) or cytokines (b). Bars represent
means and SE of treatments (n = 8). Bars with different superscripts
are different (P< 0.05).
Figure 4 Effect of sodium salicylate (Sal.C) treatment on
expression of genes in mice on low fat or high fat diet in the
epididymal adipose tissue. Epididymal tissue RNA was analyzed for
the expression of ECM genes (a) or cytokines (b). Bars represent
means and SE of treatments (n = 8). Bars with different superscripts
are different (P< 0.05).
Figure 5 Effect of diet and sodium salicylate (SS) treatment on
serum TGFβ1 concentration. Male C57BL/6J mice fed either a
control (CON) diet (10% fat calories) or a high fat diet (HFD) (60% fat
calories) for 8 weeks and provided with either plain water (Normal)
or sodium salicylate (25mg/100ml). Fasting TGFβ1 level was
determined with ELISA. Bars represent means and SE of treatments.
Bars with different superscripts are different (P< 0.05).
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ments (report in preparation), we have shown that bigly-
can directly stimulate the expression of IL-6 in
adipocytes, providing a confirmatory evidence that bigly-
can may indeed play a critical role in the expression of
inflammatory genes in AT. Possible mechanism of bigly-
can action could include direct activation of TLR4 or the
inflammasome pathways [5,8].
Although this work and our earlier report [9] clearly
shows that obesity or HFD induces the expression of
biglycan in AT, the possible implication of inflammatory
state in the regulation of biglycan expression is unknown.
We have shown that treatment with an anti-inflammatory
agent sodium salicylate led to a reduced subcutaneous
AT mass and inflammation that was associated with a
concurrent downregulation of ECM genes. Salicylate
based compounds inhibit the gene expression and protein
levels of IL-6, IL-8 and TNFα in 3T3-L1 adipocytes [19].
In this study, salicylate treatment downregulated the ex-
pression of inflammatory cytokines (IL-6 and TNFα), per-
haps due to its effect in reducing the expression of TLR4.A strong positive association between NF-kB and TLR4
expression is reported in monocytes of diabetic subjects
[20] and the downregulation of expression of TLR4 could
represent a new anti-inflammatory mechanism of effect
of salicylate, in addition to its direct inhibition of NFkB.
The downregulation of TLR4 by salicylate could have far
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in AT. For example, it is well established that free fatty
acids and other pathogen derived ligands signal through
the TLR4 in AT and perpetuate inflammation manifested
in increased expression of inflammatory cytokines such
as IL-6 and TNFα [21]. Therefore, downregulation of
TLR4 by salicylate could contribute to the reduced ex-
pression of IL-6 and TNFα observed with the salicylate
treatment. An elevated level of interleukin-10, an anti-in-
flammatory cytokine, is commonly found in obesity to
counteract the effects of inflammatory cytokines [22].
The finding of lowered IL-10 by salicylate may suggest
that, by lowering the inflammatory state, less of the anti-
inflammatory action of IL-10 was needed in the presence
of salicylate.
Although several studies have linked AT ECM gene ex-
pression with inflammatory state [6,23], none has explored
a therapy aimed at reducing both events simultaneously.
As we had hypothesized, salicylate downregulated the ex-
pression of BGN, COL6A1, and COL1A1and lowered in-
flammatory gene (IL-6, TNFα and TLR4) expression in the
subcutaneous AT. This confirms the coupling of inflam-
mation to ECM gene expression and the importance of
targeting inflammatory events in AT for obesity and fibro-
sis prevention. The relationship between ECM gene ex-
pression and inflammation appears complex.
Inflammatory environment upregulates the expression of
several ECM genes in human preadipocytes [24]. On the
other hand, there is evidence that ECM genes such as
biglycan and fibronectin are associated with induction of
inflammation [8,25,26]. Therefore, lowering inflammation
with salicylate prevents the induction of ECM gene expres-
sion by inflammatory factors. The downregulation of ECM
genes will ultimately lead to reduced adipose mass as was
observed in the subcutaneous AT depot. In this study, we
did not observe a pronounced effect of salicylate on the
epididymal AT mass and gene expression. The more
robust effect of HFD and the dampened effect of salicylate
on ECM and cytokine gene expression in the epididymal
depot reflect a potential difference between the adipose
depots and may also indicate either a need for higher dose
of salicylate or longer duration of treatment to observe sig-
nificant changes in the epididymal tissue. However, this
also raises a possibility that the effect of anti-inflammatory
compounds may first be observed in the subcutaneous AT
rather than epididymal AT. It is well recognized that the
subcutaneous adipose depot typically has reduced inflam-
matory gene expression than visceral depot [27-29]. This
could be due to the reduced adipocyte size in this depot or
may reflect a higher sensitivity to anti-inflammatory
mechanisms. In conclusion, targeting inflammatory path-
ways in AT may be an effective strategy for suppressing
ECM gene expression and for reducing AT mass and the
inflammation associated with adipocyte expansion.Abbreviation
ECM: Extracellular matrix; ELISA: Enzyme linked immunoabsorbent assay;
HFD: High fat diet; IL-6: Interleukin 6; NFκB: Nuclear factor kappa B;
TGFβ: Transforming growth factor β; TLR: Toll-like receptors; TNF: Tumor
necrosis factor.
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